Xellia Pharmaceuticals has acquired manufacturing facilities in Bedford, Ohio.
U.S. company developing biometric tattoos to potentially track health data.
Novartis’ once-daily inhaler tops GSK’s inhaler in reducing COPD.
Vertex Pharma gets expanded indication for cystic fibrosis treatment from the EC.
The NICE says it will not recommend these drugs.
FDA awards Merck KGaA and Pfizer breakthrough therapy designation for metastatic Merkel cell carcinoma treatment.
Hesperos scientists awarded international prize for accurate new alternative to animal testing of pharmaceuticals.
Global Gaucher disease treatment market value will reach $1.16 billion by 2024, says GlobalData.
Bioinformatics market to grow at CAGR of 21.2% from 2014 to 2020, according to Grand View Research, Inc.
Brickell Biotech secures exclusive world-wide rights to a novel class of RORγ inhibitors for psoriasis and other autoimmune diseases.
MediSapiens Ltd introduces BioIT solution that brings personalized medicine to treatment of cancer patients at the Helsinki University Central Hospital.
Issuance of first U.S. patent directly covering Synthetic Biologics' novel candidate for irritable bowel syndrome with constipation (IBS-C).
Salient CRGT awarded $15 million prime contract to provide IT services to the FDA Center for Veterinary Medicine.
Roche’s Genentech exercises option for Ophthotech’s muscular degeneration drug.
The changing pharmaceutical industry needs diversity, new thinking, and multi-sector experience, according to discussions at Pharma Integrates 2015.
Global type 1 diabetes mellitus market value will exceed $7 billion by 2021, says GBI Research.
The FDA approves Boehringer Ingelheim's drug for the prophylaxis of DVT and PE in patients who have undergone hip-replacement surgery.